secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001682852-24-000023
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q1 revenue $167M, net loss $1.2B; reaffirms FY 2024 sales ~$4B
----------------------------------------------------------------------

- GAAP net loss of $1.2B and diluted EPS of $(3.07) vs. $0.19 EPS a year ago.
- Spikevax product sales fell 91% YoY to $167M; $100M U.S., $67M international.
- Reaffirms 2024 product sales ~$4B; expects ~$0.3B net sales in H1 2024.
- Cash and investments $12.2B at March 31, down from $13.3B at year-end 2023.
- RSV vaccine launch targeted for fall 2024; flu vaccine filing expected in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285224000023/0001682852-24-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285224000023/mrna-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001682852-24-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer